PMID: 11921283Mar 29, 2002Paper

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters

Genes, Chromosomes & Cancer
Keiichi KondoMasahiko Hosaka

Abstract

To delineate more precisely the somatic von Hippel-Lindau disease (VHL) gene alteration as well as to elucidate its etiologic role in renal tumorigenesis, we examined a total of 240 sporadic renal cell carcinomas (RCCs) for somatic VHL gene alterations by DNA-SSCP followed by sequencing, methylation-specific PCR assay, microsatellite LOH study, and Southern blot analysis. Intragenic mutation of the VHL gene was found exclusively in clear-cell or variant-type RCCs at a frequency of 51% (104/202). Hypermethylation of the VHL promoter region was detected in an additional 11 clear-cell RCCs. Microsatellite analysis demonstrated that LOH of the VHL locus was found in 140/155 (90%) informative clear-cell RCCs. The VHL gene therefore seems to be inactivated in a two-hit manner by intragenic mutation or hypermethylation plus allelic loss in clear-cell RCC. Genomic rearrangement of the VHL gene detected by Southern analysis was not found (0/216 cases); this is in contrast to germ lines in which Southern aberrations consisted of 7-19% of the mutations. Clinicopathologic data demonstrated that VHL mutation/LOH did not vary according to tumor progression in clear-cell RCC, including tumor diameter, stage, grading, distant metastasis, and l...Continue Reading

References

May 1, 1992·Human Molecular Genetics·M H JonesY Nakamura
Jan 1, 1991·Urology·D C Merrill
Apr 1, 1985·Urology·M SchiffB Lytton
Aug 1, 1995·Nature Medicine·O IliopoulosW G Kaelin
Nov 27, 1995·International Journal of Cancer. Journal International Du Cancer·M BaillyM Ozturk
May 1, 1994·Nature Genetics·J R GnarraF M Duh
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·J G HermanW M Linehan
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Oct 18, 1996·Cell·K W Kinzler, B Vogelstein
Oct 23, 1997·The American Journal of Surgical Pathology·M AkhtarM A Ali
Jul 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·A SchoenfeldR D Burk
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·O IliopoulosW G Kaelin
Sep 24, 1999·Biochemical and Biophysical Research Communications·H OkudaT Shuin
Dec 3, 1999·Biochemical and Biophysical Research Communications·H T CohenV P Sukhatme
Jun 17, 2000·Genomics·E R WoodwardE R Maher
Sep 6, 2000·Proceedings of the National Academy of Sciences of the United States of America·T KamuraJ W Conaway
Sep 28, 2000·Biochemical and Biophysical Research Communications·T AsoS Kitajima

❮ Previous
Next ❯

Citations

Mar 7, 2007·World Journal of Urology·Christoph W M ReuterArnold Ganser
Jun 29, 2010·Targeted Oncology·Michael M Vickers, Daniel Y C Heng
Aug 7, 2010·Targeted Oncology·Bristi Basu, Tim Eisen
Feb 17, 2009·Current Oncology Reports·C Lance Cowey, W Kimryn Rathmell
Mar 28, 2008·Current Urology Reports·Rishi Sawhney, Fairooz Kabbinavar
Jan 28, 2009·Advances in Therapy·Shailender Bhatia, John A Thompson
Nov 30, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Wani Arjumand, Sarwat Sultana
Jun 20, 2003·Lancet·Russell R LonserEdward H Oldfield
Mar 3, 2009·Nature Medicine·Yi WangMichael Ohh
Apr 7, 2010·Nature Reviews. Clinical Oncology·Lucy Gossage, Tim Eisen
Feb 27, 2010·The Journal of Biological Chemistry·Tricia M Wright, W Kimryn Rathmell
Oct 21, 2003·DNA and Cell Biology·Benjamin I ChungTerence W McGarvey
Feb 8, 2013·Japanese Journal of Clinical Oncology·Yoji NagashimaMasahiro Yao
Apr 9, 2008·American Journal of Clinical Oncology·Rachel P RiechelmannJennifer J Knox
Jan 1, 2010·Therapeutic Advances in Medical Oncology·Daniel Y C HengKim N Chi
Jan 12, 2013·BMC Cancer·Christudas MoraisGlenda C Gobe
Nov 13, 2004·American Journal of Clinical Pathology·Luigi SchipsCord Langner
Aug 5, 2011·Drugs & Aging·Sumanta K PalRobert A Figlin
Dec 4, 2012·International Journal of Molecular Sciences·Guadalupe Aparicio GallegoLuís M Antón Aparicio
May 30, 2009·Current Oncology·D Y C Heng, C Kollmannsberger
Jan 22, 2014·Medical Oncology·Francesca LessiGeneroso Bevilacqua
Jul 17, 2014·Virchows Archiv : an International Journal of Pathology·Mariana Rezende AlvesRafael Malagoli Rocha
May 14, 2014·Clinical Genitourinary Cancer·Husain K KhambatiUNKNOWN International mRCC Database Consortium
Mar 14, 2012·Proceedings of the National Academy of Sciences of the United States of America·Yi WangMichael Ohh
Dec 26, 2006·Expert Review of Anticancer Therapy·Martin E GoreAna Montes
Dec 13, 2005·Expert Review of Anticancer Therapy·W Kimryn RathmellBrian I Rini
Sep 22, 2010·The Journal of Cell Biology·Claudio R ThomaGaudenz Danuser
Apr 1, 2003·Expert Opinion on Investigational Drugs·Mayer Fishman, Scott Antonia
Mar 1, 2008·Expert Opinion on Drug Discovery·C Lance Cowey, W Kimryn Rathmell
Aug 25, 2015·European Urology·Johannes SchödelDavid R Mole
Jun 24, 2009·Cancer Investigation·Yu-Xiang LiangWei-de Zhong
Jul 19, 2011·Hematology/oncology Clinics of North America·Patricia A TangDaniel Y C Heng
Mar 1, 2009·Surgical Pathology Clinics·S Joseph Sirintrapun, Anil V Parwani
Sep 20, 2008·Cancer Treatment Reviews·Fernando Cotait MalufAntonio Carlos Buzaid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.